TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
A new generation of interactive formulation development platforms can leave trial and error in the formulation process in the past. Development of any new drug ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the ...
Appropriate drug formulation is a prerequisite for successful drug development. CD Formulation, a highly specialized CRO service provider, recently announced its capability of offering one-stop ...
There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too. Traditional drug development is costly and time-consuming, with many hours, ...
Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz "Taltz has long delivered effective treatment with a well-established safety profile that ...
The global formulation development outsourcing industry was estimated at $22.5 billion in 2021, and is anticipated to hit $51.9 billion by 2031, registering a CAGR of 9% from 2022 to 2031. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback